IMR Press / FBL / Volume 28 / Issue 6 / DOI: 10.31083/j.fbl2806131
Open Access Original Research
CRISPR/Cas9-Mediated Gene Correction in Osteopetrosis Patient-Derived iPSCs
Show Less
1 Clinical Medical Research Center, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), 518020 Shenzhen, Guangdong, China
2 Institute of Nephrology and Blood Purification, The First Affiliated Hospital, Jinan University, 510632 Guangzhou, Guangdong, China
3 Central Laboratory, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, 541001 Guilin, Guangxi, China
4 Clinical Lab of Shenzhen Pingshan People's Hospital, Shenzhen Pingshan People's Hospital, 518118 Shenzhen, Guangdong, China
*Correspondence: gdszpsrmyy@163.com (Peng Zhu); donge66@126.com (Donge Tang); daiyong22@aliyun.com (Yong Dai)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2023, 28(6), 131; https://doi.org/10.31083/j.fbl2806131
Submitted: 20 December 2022 | Revised: 5 March 2023 | Accepted: 14 March 2023 | Published: 30 June 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: Osteopetrosis represents a rare genetic disease with a wide range of clinical and genetic heterogeneity, which results from osteoclast failure. Although up to 10 genes have been identified to be related with osteopetrosis, the pathogenesis of osteopetrosis remains foggy. Disease-specific induced pluripotent stem cells (iPSCs) and gene-corrected disease specific iPSCs provide a platform to generate attractive in vitro disease cell models and isogenic control cellular models respectively. The purpose of this study is to rescue the disease causative mutation in osteopetrosis specific induced pluripotent stem cells and provide isogenic control cellular models. Methods: Based on our previously established osteopetrosis-specific iPSCs (ADO2-iPSCs), we repaired the point mutation R286W of the CLCN7 gene in ADO2-iPSCs by the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) mediated homologous recombination. Results: The obtained gene corrected ADO2-iPSCs (GC-ADO2-iPSCs) were characterized in terms of hESC-like morphology, a normal karyotype, expression of pluripotency markers, homozygous repaired sequence of CLCN7 gene, and the ability to differentiate into cells of three germ layers. Conclusions: We successfully corrected the point mutation R286W of the CLCN7 gene in ADO2-iPSCs. This isogenic iPSC line is an ideal control cell model for deciphering the pathogenesis of osteopetrosis in future studies.

Keywords
CRISPR/Cas9
gene correction
osteopetrosis
iPSCs
CLCN7
Funding
82060393/National Natural Science Foundation of China
JCYJ20180305163846927/Science and Technology Plan of Shenzhen
2020GXNSFAA159124/Natural Science Foundation of Guangxi
202139/Scientific Research Project of Health System in Pingshan District of Shenzhen
Figures
Fig. 1.
Share
Back to top